Taxotere® for Breast Cancer
On August 18, 2004, the FDA approved docetaxel for injection (Taxotere®, a
trademark of Aventis Pharmaceuticals, Inc.) for use in combination with
doxorubicin and cyclophosphamide for the
adjuvant
treatment
of women with operable node-positive breast cancer.
Investigators enrolled 1491 women with node positive operable breast cancer in
an international, multicenter, randomized trial (TAX316). Patients were
stratified according to the number of positive axillary lymph nodes (1-3, 4+)
and were randomly allocated to receive adjuvant treatment with either docetaxel
75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide
500 mg/m2 (TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2
and cyclophosphamide 500 mg/m2 (FAC arm). Both regimens were given every 3
weeks for 6 cycles. After the last cycle of chemotherapy, patients with
positive estrogen and/or progesterone receptors received tamoxifen 20 mg daily
for up to 5 years.
The primary endpoint, disease free survival (DFS), included local and distant
recurrences,
contralateral
breast cancer and deaths from
any cause. At a median follow up of 55 months, results from a second interim
analysis showed that the TAC regimen has significantly longer DFS than FAC,
with an overall reduction in risk of relapse of 25.7% (hazard ratio= 0.74;
2-sided 95% CI= 0.60, 0.92, stratified log rank p = 0.0047). At the time of
this interim analysis, based on 219 deaths, overall survival was longer for TAC
than FAC (hazard ratio=0.69, 2-sided 95% CI=0.53, 0.90). There will be further
analysis at the time survival data mature.
Women receiving TAC had an increase in anemia, grade > 3 neutropenia,
stomatitis, amenorrhea, fever in absence of infection, hypersensitivity
reactions, peripheral edema, neurosensory and skin events compared to those
receiving FAC. The toxicity, while significant, did not cause a large number of
patients to withdraw from treatment. As with other
anthracycline/cyclophosphamide-containing regimens, long-term serious toxicity
for the TAC regimen included leukemia (0.4%) and congestive heart failure
(1.6%).
The approved dose of docetaxel for the adjuvant treatment of operable
node-positive breast cancer is 75 mg/m2 administered 1-hour after doxorubicin
50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks for 6 cycles.
Full prescribing information
is available, including
clinical trial information, safety, dosing, drug-drug interactions and
contraindications.
Back to Top
< Previous Section | Next Section > |